Connect Biopharma Holdings Ltd (CNTB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has a cash flow conversion efficiency ratio of -0.376x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.00 Million) by net assets ($42.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Connect Biopharma Holdings Ltd to measure how much of total assets are equity-financed.
Connect Biopharma Holdings Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Connect Biopharma Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Connect Biopharma Holdings Ltd (CNTB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Connect Biopharma Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alpha Cognition Inc
NASDAQ:ACOG
|
-0.158x |
|
Mnc Investama Tbk
JK:BHIT
|
0.006x |
|
John Hancock Income Securities Closed Fund
NYSE:JHS
|
0.031x |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
0.020x |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
0.062x |
|
AMIA Co. Ltd.
TW:8438
|
0.062x |
|
Energy World Corporation Ltd
AU:EWC
|
-0.017x |
|
DMS Co.Ltd
KQ:068790
|
0.056x |
Annual Cash Flow Conversion Efficiency for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Connect Biopharma Holdings Ltd from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see CNTB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $41.98 Million | $-51.21 Million | -1.220x | -376.12% |
| 2024-12-31 | $92.17 Million | $-23.61 Million | -0.256x | +45.75% |
| 2023-12-31 | $101.50 Million | $-47.93 Million | -0.472x | +25.08% |
| 2022-12-31 | $157.49 Million | $-99.27 Million | -0.630x | +68.51% |
| 2021-12-31 | $272.26 Million | $-544.93 Million | -2.002x | -287.84% |
| 2020-12-31 | $-24.03 Million | $-25.61 Million | 1.066x | -49.67% |
| 2019-12-31 | $-6.18 Million | $-13.09 Million | 2.117x | -40.46% |
| 2018-12-31 | $-19.41 Million | $-69.03 Million | 3.556x | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.